Window of Opportunity: A New Insight into Sequential Bevacizumab and Paclitaxel in Two Cases of Metastatic Triple-negative Breast Cancer

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2015 Dec 2

PMID 26622409

Citations 5

Authors

Dar-Ren Chen

Che Lin

Yu-Fen Wang

Affiliations

Soon will be listed here.

Abstract

Bevacizumab, an antiangiogenic monoclonal antibody against vascular endothelial growth factor, was designed to normalize tumor vasculature and reduce intratumoral pressure. It can create a 'normalization window' during which the cancer can be attacked the most effectively, and the effects of chemotherapeutic drugs are enhanced. Representative trials (E2100, AVADO, RIBBON-1, RIBBON-2 and TURANDOT) have shown that the addition of bevacizumab to chemotherapy has significant benefits on progression-free survival for metastatic breast cancer, but not on overall survival. The present study describes two patients with metastatic triple-negative breast cancer who received 6 courses of bevacizumab-containing chemotherapy. Each course comprised 5-7.5 mg/kg bevacizumab administered on days 1 and 15, and 20-24 h after bevacizumab delivery, 80 mg/m paclitaxel was administered for 3 weeks on days 2, 9 and 16, followed by 1 week of rest. Following sequential treatment with bevacizumab and paclitaxel, the results of computed tomography showed that the tumors were rapidly reduced in size. Based on the imaging findings from three-dimension power Doppler ultrasonography in one of the breast cancer patients who received neoadjuvant chemotherapy with bevacizumab, the possible timing of the normalization window was 20-24 h after the administration of bevacizumab. The normalization window may provide an opportunity to enhance the effect of chemotherapy with the aid of bevacizumab.

Citing Articles

Is Sphingosine-1-Phosphate a Regulator of Tumor Vascular Functionality?.

Karam M, Ives A, Auclair C Cancers (Basel). 2022; 14(5).

PMID: 35267610 PMC: 8909747. DOI: 10.3390/cancers14051302.

Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy.

Li S, Zhang Q, Hong Y Technol Cancer Res Treat. 2020; 19:1533033820980116.

PMID: 33287656 PMC: 7727091. DOI: 10.1177/1533033820980116.

Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography.

Yang Z, Kang M, Zhu S, Huang J, Li X, Wang R Onco Targets Ther. 2018; 11:7909-7917.

PMID: 30510431 PMC: 6231431. DOI: 10.2147/OTT.S181842.

Monitoring of tumor vascular normalization: the key points from basic research to clinical application.

Li W, Quan Y, Li Y, Lu L, Cui M Cancer Manag Res. 2018; 10:4163-4172.

PMID: 30323672 PMC: 6175544. DOI: 10.2147/CMAR.S174712.

Antiangiogenic cancer treatment: The great discovery and greater complexity (Review).

Maj E, Papiernik D, Wietrzyk J Int J Oncol. 2016; 49(5):1773-1784.

PMID: 27826619 PMC: 5063425. DOI: 10.3892/ijo.2016.3709.

References

Pugh C, Ratcliffe P . Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003; 9(6):677-84. DOI: 10.1038/nm0603-677. View

Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain R . Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A. 1996; 93(25):14765-70. PMC: 26210. DOI: 10.1073/pnas.93.25.14765. View

Jain R . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7(9):987-9. DOI: 10.1038/nm0901-987. View

Jain R . Taming vessels to treat cancer. Sci Am. 2008; 298(1):56-63. DOI: 10.1038/scientificamerican0108-56. View

Dickler M, Barry W, Cirrincione C, Ellis M, Moynahan M, Innocenti F . Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016; 34(22):2602-9. PMC: 5012690. DOI: 10.1200/JCO.2015.66.1595. View

Gianni L, Romieu G, Lichinitser M, Serrano S, Mansutti M, Pivot X . AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013; 31(14):1719-25. DOI: 10.1200/JCO.2012.44.7912. View

Goel S, Wong A, Jain R . Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012; 2(3):a006486. PMC: 3282493. DOI: 10.1101/cshperspect.a006486. View

Robert N, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O . RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011; 29(10):1252-60. DOI: 10.1200/JCO.2010.28.0982. View

Miles D, de Haas S, Dirix L, Romieu G, Chan A, Pivot X . Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013; 108(5):1052-60. PMC: 3619079. DOI: 10.1038/bjc.2013.69. View

10.

Winkler F, Kozin S, Tong R, Chae S, Booth M, Garkavtsev I . Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6(6):553-63. DOI: 10.1016/j.ccr.2004.10.011. View

11.

Miles D, Chan A, Dirix L, Cortes J, Pivot X, Tomczak P . Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28(20):3239-47. DOI: 10.1200/JCO.2008.21.6457. View

12.

Vakoc B, Lanning R, Tyrrell J, Padera T, Bartlett L, Stylianopoulos T . Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med. 2009; 15(10):1219-23. PMC: 2759417. DOI: 10.1038/nm.1971. View

13.

Giuliano S, Pages G . Mechanisms of resistance to anti-angiogenesis therapies. Biochimie. 2013; 95(6):1110-9. DOI: 10.1016/j.biochi.2013.03.002. View

14.

Goel S, Duda D, Xu L, Munn L, Boucher Y, Fukumura D . Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011; 91(3):1071-121. PMC: 3258432. DOI: 10.1152/physrev.00038.2010. View

15.

Hegde P, Jubb A, Chen D, Li N, Meng Y, Bernaards C . Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res. 2012; 19(4):929-37. DOI: 10.1158/1078-0432.CCR-12-2535. View

16.

Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S . Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol. 2013; 14(2):125-33. DOI: 10.1016/S1470-2045(12)70566-1. View

17.

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E . Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357(26):2666-76. DOI: 10.1056/NEJMoa072113. View

18.

Brufsky A, Hurvitz S, Perez E, Swamy R, Valero V, ONeill V . RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic.... J Clin Oncol. 2011; 29(32):4286-93. DOI: 10.1200/JCO.2010.34.1255. View

19.

Willett C, Boucher Y, Tomaso E, Duda D, Munn L, Tong R . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10(2):145-7. PMC: 2693485. DOI: 10.1038/nm988. View